Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of ICE vs CapOx in gemcitabine-resistant pancreatic cancer
2009-014407-31Phase 2Terminated
- Sponsor
- University Hospital Odense
- Start
- Sep 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, cetuximab, everolimus, capecitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Overall survival. Started Sep 2009; status: terminated.
02
Drugs
irinotecancetuximabeverolimuscapecitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2009-014407-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014407-31.